IceCure Medical (ICCM) Registration Filing summary

Company overview and business model

• Commercial-stage medical device company specializing in cryoablation systems using liquid nitrogen for tumor treatment, offering minimally invasive alternatives to surgery for various tumor types, with ProSense as the lead product.

• Focused on expanding indications, including early-stage breast cancer, with recent FDA panel support and ongoing regulatory engagement.

• Operations are based in Israel, with global reach and products marketed internationally.

Financial performance and metrics

• Product sales for the three and six months ended June 30, 2025, were approximately $525,000 and $1.25 million, respectively.

• Lower sales and gross profit for the first half of 2025 due to regional conflict and loss of Japanese distribution revenue, resulting in a higher net loss compared to the same period in 2024.

• As of March 31, 2025, had $6.0 million in cash and cash equivalents and an accumulated deficit of $109.0 million.

Use of proceeds and capital allocation

• Net proceeds of approximately $9.3 million (if fully subscribed) will be used to repay a $2 million bridge loan and for general corporate and working capital purposes.

• Management retains broad discretion over allocation of proceeds.